News
José Baselga, Named as Bristol-Myers Squibb’s M.D., Ph.D. to Board of Directors
Bristol-Myers Squibb Company announced that its Board of Directors has elected José Baselga, M.D., Ph.D., to the Board, effective March 1, 2018. Dr. Baselga will serve as a member of Science & Technology Committee of the Board of Directors....
News
Novartis shareholders grant all resolutions projected by Board of Directors at the Annual General Meeting
Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the Group's Annual General Meeting (AGM). A total of 1,731 shareholders were present at the meeting held in Basel, representing approximately 62.6% of the...
News
Advanced Laboratory Management System Now Available on a Global Scale
Laboratory scientists across the globe can now benefit from a software system that helps them manage the entire lab, designed to support process adherence, data integrity and complete regulatory compliance. With advanced functionality for sample management...
News
AbbVie increases 9.7% since earning reports: Can it persist?
A month has gone by since the last earnings report for AbbVie Inc. ABBV . Shares have added about 9.7% in that time frame, outperforming the market. Will the recent positive trend continue leading up to...
News
Gut bacteria can ascend your obesity: Journal of Clinical Endocrinology and Metabolism
According to the study published in the Journal of Clinical Endocrinology and Metabolism, the presence of gut flora may be healthy for some people, while it may increase the risk of obesity in others. The animal...
News
Shire groups up with Microsoft and EUORORDIS to work on a rare disease project
On average its rare disease patients – around half of whom are children – have to wait for five years before they receive the correct diagnosis for their condition. To help tackle this diagnostic lag and...
News
Merck shares plunges after losing to Gilead
Merck & Co. fell after a federal judge tossed a record $2.54 billion verdict it had won against Gilead Sciences Inc. over a hepatitis treatment. A federal jury in 2016 had said that Gilead owed Merck...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read